WO2012112842A3 - Compositions et procédés pour traiter le poliovirus - Google Patents

Compositions et procédés pour traiter le poliovirus Download PDF

Info

Publication number
WO2012112842A3
WO2012112842A3 PCT/US2012/025571 US2012025571W WO2012112842A3 WO 2012112842 A3 WO2012112842 A3 WO 2012112842A3 US 2012025571 W US2012025571 W US 2012025571W WO 2012112842 A3 WO2012112842 A3 WO 2012112842A3
Authority
WO
WIPO (PCT)
Prior art keywords
poliovirus
methods
compositions
treating
antigen
Prior art date
Application number
PCT/US2012/025571
Other languages
English (en)
Other versions
WO2012112842A2 (fr
Inventor
Zhaochun Chen
Robert H. Purcell
Konstantin Chumakov
Original Assignee
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services filed Critical The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services
Publication of WO2012112842A2 publication Critical patent/WO2012112842A2/fr
Publication of WO2012112842A3 publication Critical patent/WO2012112842A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps chimériques chimpanzé/humain et leurs fragments de liaison à l'antigène qui sont capables de neutraliser le poliovirus. En outre, elle concerne également des procédés d'utilisation des anticorps et de leurs fragments de liaison à l'antigène pour prévenir et traiter une infection par le poliovirus.
PCT/US2012/025571 2011-02-17 2012-02-17 Compositions et procédés pour traiter le poliovirus WO2012112842A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443915P 2011-02-17 2011-02-17
US61/443,915 2011-02-17

Publications (2)

Publication Number Publication Date
WO2012112842A2 WO2012112842A2 (fr) 2012-08-23
WO2012112842A3 true WO2012112842A3 (fr) 2013-01-31

Family

ID=45953219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025571 WO2012112842A2 (fr) 2011-02-17 2012-02-17 Compositions et procédés pour traiter le poliovirus

Country Status (1)

Country Link
WO (1) WO2012112842A2 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN ZHAOCHUN ET AL: "Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 103, no. 6, 7 February 2006 (2006-02-07), pages 1882 - 1887, XP002389476, ISSN: 0027-8424, DOI: 10.1073/PNAS.0510598103 *
CHEN ZHAOCHUN ET AL: "Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.", JOURNAL OF VIROLOGY MAY 2011 LNKD- PUBMED:21345966, vol. 85, no. 9, May 2011 (2011-05-01), pages 4354 - 4362, XP002682219, ISSN: 1098-5514 *
CHU C-T ET AL: "A HUMAN-HUMAN HYBRIDOMA WHICH PRODUCES ANTIBODIES TO POLIOVIRUSES", PROCEEDINGS OF THE NATIONAL SCIENCE COUNCIL REPUBLIC OF CHINA PART B LIFE SCIENCES, vol. 13, no. 4, 1989, pages 284 - 288, XP009162216, ISSN: 0255-6596 *
SCHOFIELD D J ET AL: "Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis a virus.", VIROLOGY 5 JAN 2002 LNKD- PUBMED:11878915, vol. 292, no. 1, 5 January 2002 (2002-01-05), pages 127 - 136, XP002965366, ISSN: 0042-6822 *
UHLIG H ET AL: "Intertypic cross-neutralization of polioviruses by human monoclonal antibodies", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 163, no. 1, 1 March 1988 (1988-03-01), pages 214 - 217, XP023047507, ISSN: 0042-6822, [retrieved on 19880301], DOI: 10.1016/0042-6822(88)90251-6 *

Also Published As

Publication number Publication date
WO2012112842A2 (fr) 2012-08-23

Similar Documents

Publication Publication Date Title
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
WO2012145183A3 (fr) Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EP2582722A4 (fr) Anticorps contre gd2
WO2012149356A3 (fr) Anticorps anti-cd40 et leurs procédés d'utilisation
WO2013056148A3 (fr) Procédés d'utilisation d'antagonistes de scd1
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
PH12014502406B1 (en) Anti-il-23p19 antibodies
EP2755721A4 (fr) Système et méthode de traitement de la peau et des tissus sous-jacents pour améliorer leur santé, leur fonction et/ou leur aspect
MX354988B (es) Formulaciones de anticuerpo y metodos.
WO2014200898A3 (fr) Protéines se liant à l'antigène neutralisant le cmv
MX2011010707A (es) Anticuerpos dkk-1.
WO2013022740A3 (fr) Ligands de gpr35 et leurs utilisations
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PH12014502628B1 (en) Compositions and methods related to the prevention and treatment of rabies infection
GB201109238D0 (en) Antibodies
WO2013106689A8 (fr) Inhibiteurs de la protéase ns3 du vhc
WO2013090635A3 (fr) Composition et méthode pour le diagnostic et le traitement de troubles liés au fer
PH12015501360A1 (en) Bmp-6 antibodies
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
WO2014064609A3 (fr) Composition de plante médicinale pour la prévention et le traitement de maladies à médiation par le tnf-α

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12714097

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12714097

Country of ref document: EP

Kind code of ref document: A2